250 results about "White blood cell" patented technology

The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

This invention relates to a method and application for enriching circulating tumor cells (CTCs) based on ambient temperature mechanical perfusion technology, belonging to the field of biomedical technology. The method comprises the following steps: flushing the liver resected during liver transplantation via the portal vein and hepatic artery, connecting it to an ambient temperature mechanical perfusion loop, and performing in vitro perfusion using simulated blood perfusion fluid; when perfusion exceeds 2 hours and the lactate content drops to <5 mmol / L, collecting the simulated blood perfusion fluid; and sequentially subjecting the simulated blood perfusion fluid to centrifugation, red blood cell removal, and white blood cell removal to obtain enriched circulating tumor cells (CTCs) for liver cancer. A human liver cancer ex vivo organ perfusion model is constructed using NMP technology to fully recreate the tumor microenvironment and CTC generation process, and the large volume of perfusion fluid is processed to achieve efficient enrichment of CTCs.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and / or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice.

Chimeric antigen receptors (CARs) that bind to Human Leukocyte Antigen (HLA)-pan DP, cells that comprise the CARS and methods of making and using the cells are provided.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application provides a stem cell collector, which comprises a body and two extrusion devices, the body has two inner cavities, a front side wall of the body is formed with two extrusion surfaces, the extrusion surfaces are provided with openings in communication with the inner cavities, and the two extrusion devices are arranged on the body and correspond to one extrusion surface respectively. The extrusion device comprises an extrusion plate, a first moving assembly, a partition plate, a second moving assembly, an extrusion block, a third moving assembly and a driving mechanism. The stem cell collector can automatically extrude a blood bag, facilitates the collection of a solution containing a plasma layer, a white blood cell and platelet layer and a small part of a red blood cell layer, reduces the mixing of the red blood cell layer, improves the collection efficiency and brings convenience for the collection of stem cells.

The present invention relates to methods of administering a cyclic peptide inhibitor of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding compositions, assays, methods, and / or uses for treatment of psoriasis.

The invention provides a bispecific antibody and application thereof. The bispecific antibody comprises a first structural domain and a second structural domain, wherein the first structural domain is specifically combined with an interleukin-6 receptor IL-6R, and the second structural domain is specifically combined with interleukin-23. The bispecific antibody can target IL-6R and IL-23p19 at the same time, the specificity is higher, tumor cells can be targeted more accurately, adverse reactions caused by off-target toxicity are reduced, the special function is exerted, the biological function which is difficult to achieve by monoclonal antibody drugs is achieved, compared with a combination therapy of monoclonal antibodies, the treatment cost can be effectively reduced, and the treatment effect is better. The upper limit of the curative effect on autoimmune diseases such as rheumatoid arthritis and IBD at present is broken through.

The application relates to the technical field of biological medicine, in particular to a genetically modified immune cell and construction and application thereof. The genetically modified immune cell expresses a target protein, the target protein comprises a chimeric antigen receptor and a membrane-bound interleukin, the chimeric antigen receptor comprises an antigen binding domain specifically combined with GPC3, and the membrane-bound interleukin comprises a membrane-bound IL-7. The application simultaneously overexpresses the GPC3CAR and the membrane-bound IL-7, improves the killing ability of TILs on tumor cells, simultaneously improves the expansion ability of immune cells in vivo and in vitro, the ability of continuously killing tumors, and is more conducive to improving the treatment effect of immune cells on GPC3-positive tumors.

An mRNA composition for treating cancer is provided. The mRNA composition for treating cancer includes an mRNA encoding a CD47-targeted chimeric antigen receptor (CAR) and an mRNA encoding interleukin-12 (IL-12).

The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.

Provided is a bispecific antibody, comprising: a first domain that specifically binds interleukin-6 receptor (IL-6R), and a second domain that specifically binds TNF- like ligand la (TL1 A). Also provided is a method of the bispecific antibodies for the treatment or prevention of diseases associated with IL-6R and / or TL1 A.

The system comprises a laminated 5 diagnostic strip including a backing layer (105), an absorbent pad layer (106) configured for controlled capillary transport of milk, and a reagent deposit layer (107) defining multiple spatially separated dry reagent zones. The reagent zones include a pH indicator zone (101), a leukocyte esterase detection zone (102), a hemoglobin detection zone (103), and a nitrite detection zone (104), each adapted 10 for operation in the milk matrix. A calibrated sample application point (108) receives a predefined volume of untreated milk and fluidically communicates the sample to the reagent zones via the absorbent pad layer. Colorimetric reactions develop in a result window area (109), enabling simultaneous visual interpretation without analytical instruments, typically within three minutes. The invention further 15 includes a moisture-controlled storage container comprising desiccant elements (204, 205), a reference color chart (208), and a calibrated pipette (209), ensuring reagent stability and standardized use.

The present invention relates to the use of an anti-interleukin-6 agent prior to, simultaneously with, or after a CRS inducing immunotherapeutic agent.

The present invention relates to a compound of the chemical formula (1a): (1a) The invention relates to or its enantiomers, racemic mixtures, or pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition comprising a compound of formula (1a), its enantiomers, racemic mixtures, or pharmaceutically acceptable salts, and one or more pharmaceutically acceptable excipients, and a method for treating autoimmune diseases, central nervous system diseases, and leukocyte disorders, comprising the step of administering the pharmaceutical composition of the invention to an individual in need.

This disclosure provides IL-15 fusion proteins and compositions comprising IL-15 fusion proteins. This disclosure further provides methods for treating and / or preventing immunodeficiency in subjects, as well as methods for cancer immunotherapy, which include administering fusion proteins as described herein.

Pharmaceutical compositions comprising anti-interleukin 12 (IL-12) interleukin 23 (IL-23) antibodies are described. The pharmaceutical compositions may comprise molecular attributes, such as oxidation of light chain W32, isoaspartic acid at heavy chain position D55; high molecular weight species such as dimers and / or oligomers, high mannose, sialylation, or acidic peak species. Method comprising administering the pharmaceutical compositions are described. Methods of manufacturing the pharmaceutical compositions are described.

This invention discloses a method, apparatus, storage medium, and device for identifying full-path blockage in dual-impedance channels. The method includes: establishing a functional relationship between the voltage of a red blood cell impedance channel and the voltage of a white blood cell impedance channel; obtaining the current red blood cell impedance channel voltage and the current white blood cell impedance channel voltage at the current temperature; obtaining the target white blood cell impedance channel voltage based on the current red blood cell impedance channel voltage and the functional relationship; determining the absolute value of the difference between the current white blood cell impedance channel voltage and the target white blood cell impedance channel voltage; if the absolute value of the difference is greater than or equal to a first preset threshold and the difference is less than 0, then outputting full-path blockage information for the red blood cell impedance channel; if the absolute value of the difference is greater than or equal to the first preset threshold and the difference is greater than 0, then outputting full-path blockage information for the white blood cell impedance channel. This method can ensure that the voltage of the impedance channel is independent of temperature and can accurately identify whether full-path blockage has occurred in the impedance channel.

Provided are bispecific antibodies comprising first and second VIIII binding domains that specifically bind to the extracellular domains of interleukin- 10 receptor (IL-10R) alpha subunit (IL-10Rα) and beta subunit (IL-10Rβ), and that selectively suppress activation of myeloid cells and induce minimal or no direct activation of T cells or B cells.

The present disclosure relates to antigen binding proteins that bind to one or more cytokines. In particular, the present disclosure provides interleukin 13 (IL-13) binding proteins as well as multispecific antigen binding proteins comprising an IL-13 binding domain. The present disclosure further relates to the use of said binding proteins in medicine.